November 15, 2013: U.S. equity markets opened higher Friday morning even following a dismal report on the Empire State manufacturing index, a lower-than-expected reading on U.S. industrial production, and a drop in U.S. export prices. Sharply higher readings on wholesale inventories promise increased estimates for fourth-quarter GDP growth. Both the DJIA and the S&P 500 indexes closed at new highs today.
European markets closed mostly higher today, while Asian and Latin American markets all closed higher.
Monday�� calendar includes speeches by Boston Fed President Eric Rosengren, New York Fed President William Dudley, Philadelphia Fed President Charles Plosser, and Minneapolis Fed President Narayana Kocherlakota and the following scheduled data releases and events (all times Eastern):
9:00 a.m. – Treasury International Capital (TIC) data 10:00 a.m. – Housing market index 10:00 a.m. – E-commerce retail sales 11:30 a.m. – 3- and 6-month bill auctionsHere are the closing bell levels for Friday:
Top 5 Wireless Telecom Companies To Own In Right Now: Progress Software Corporation(PRGS)
Progress Software Corporation operates as an enterprise software company worldwide. Its products include Progress OpenEdge platform, which offers development tools, application servers, application management tools, and an embedded database; Progress Orbix to address enterprise integration problems with standards-based solutions; and Progress ObjectStore, an object data management system to store data faster than relational database management system or file-based storage system. The company?s products also comprise Progress Responsiveness Process Management suite for business users; Progress Control Tower, an interactive business control panel; Progress Sonic, which comprises an enterprise messaging system and the enterprise service buses; Progress Actional that provides operational and business visibility, root cause analysis, and policy-based security and control of services; Progress Apama, which offers tools for creating, testing, and deploying strategies for applicat ions, including algorithmic trading, market aggregation, smart order routing, market surveillance and monitoring, and risk management; Progress Savvion BusinessManager, a business process management software; and Fuse products that provide customers with access to professional open source integration and messaging software. In addition, it offers Progress DataDirect Connect products, which provide data connectivity components; Progress DataDirect Shadow to provide foundation architecture for standards-based mainframe integration; and Progress Data Services product set that offers data integration for distributed applications. Further, the company provides maintenance, consulting, training, and customer support services. Progress Software Corporation sells its products to independent software vendors, original equipment manufacturers, and system integrators through direct sales force and independent distributors. The company was founded in 1981 and is based in Bedford, Massac husetts.
Advisors' Opinion:- [By Garrett Cook]
In trading on Friday, technology shares were relative leaders, up on the day by about 0.15 percent. Top gainers in the sector included Aware (NASDAQ: AWRE), up 15.9 percent, and Progress Software (NASDAQ: PRGS), up 10.5 percent.
Top Asian Companies To Watch For 2014: ITonis Inc (ITNS)
ITonis Inc., incorporated on July 5, 2005, operates as a holding company. The Company focuses to purchase entrepreneurial companies that have established themselves, or are expected to establish themselves in various markets.
The Company invests in small growth entrepreneurial companies. In May 2011, the Company acquired Performance Mortgage Group, Inc., as a wholly owned subsidiary.
Advisors' Opinion:- [By Peter Graham]
What�� the Catch With MyEcheck Inc? According to various disclosures, transactions of $500 and $2k have or will occur to mention MyEcheck Inc in various investment newsletters. The most recent news for MyEcheck Inc is not so recent as it dates from last April and was an announcement that the company would license its proprietary system to other operators for a share of their transaction revenue on the system with the CEO pointing out: ��n addition to our processing revenue, we will have licensing revenue that will exceed our processing revenue in a relatively short period of time." However, a quick look at MyEcheck Inc�� financials reveals revenues of $3k (most recent reported quarter), zero, zero and zero for the past four quarters along with net income of $387k (most recent reported quarter) and net losses of $8k, $35k and $14k. At the end of last June, MyEcheck Inc had no cash to cover $804k in current liabilities. So maybe investor will want to wait for evidence of licensing and processing revenue to materialize.
ITonis Inc (OTCMKTS: ITNS) Recently Announced Its First OrderSmall cap ITonis Inc is an Orange County, California based holding company established in 2005 that's is currently undergoing a company-wide transformation to embark upon an aggressive acquisition plan to purchase high growth entrepreneurial companies that have established themselves, or are expected to establish themselves as leaders in various market niches. On Friday, ITonis Inc fell 9.09% to $0.003 for a market cap of $2.56 million plus ITNS is down 80.3% over the past year and down 50% over the past five years according to Google Finance.
Top Asian Companies To Watch For 2014: CCR SA (CCRO3)
CCR SA is a Brazil-based holding company primarily engaged in the operation of highways. The Company's businesses are divided into five main operating segments: Highway which includes concessions such as AutoBAn, ViaOeste, NovaDutra, RodoNorte, SPVias, Ponte, ViaLagos, RodoAnel Oeste, Transolimpica and Renovias; Subway which includes ViaQuatro, Sea Transportation which includes Barcas concession; Airport Concessions which include Quiport, Aeris and CAP, and all companies related to these concessions; and Services/Holdings which is related to sub-holdings CPC and CCR Espana, among others. It is involved in the collection of toll fees on highways and is responsible for repairing, conserving, maintaining and operating of these highways. It is responsible for national highways network in Brazilian states of Sao Paulo, Rio de Janeiro and Parana. Additionally, it is active in automotive inspection services, automatic toll payment and automatic vehicle identification systems operation. Advisors' Opinion:- [By Ney Hayashi]
Toll-road operator CCR SA (CCRO3) added 3.1 percent to 16.75 reais, snapping a five-day rout that drove shares 11 percent lower. Competitor EcoRodovias Infraestrutura e Logistica SA gained 1.7 percent to 14.75 reais today.
Top Asian Companies To Watch For 2014: Galena Biopharma Inc (GALE)
Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).
The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.
In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.
The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.
The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.
Advisors' Opinion:- [By Michael Douglass and David Williamson]
Galena Biopharma� (NASDAQ: GALE ) announced this morning that it has licensed the rights to sell Zuplenz for $5 million in stock and cash, in addition to royalties, milestones, and an upfront payment.
- [By James E. Brumley]
It may look like little more than a choppy mess with just a quick glance at Galena Biopharma Inc. (NASDAQ:GALE). But, the more you study the chart - and the company - the more you realize there's enough long-term potential from the company's pipeline to keep spurring GALE in a generally-upward direction. In fact, the bulls look like they're on the verge of taking Galena Biopharma out of second gear and putting it into third. As such, it may not be a bad bet at this point.
- [By Sean Williams]
The waiting game
The tables are clearly stacked against small biotech companies developing cancer drugs. History has shown that few (if any) have successfully had the Food and Drug Administration approve a late-stage cancer drug. While mid-stage trials of Galena Biopharma's (NASDAQ: GALE ) HER2-targeting breast cancer vaccine have been promising thus far, the chances of an approval seem a long way off.
Top Asian Companies To Watch For 2014: Rentech Inc (RTK)
Rentech, Inc. (Rentech), incorporated in 1981, is a provider of clean energy solutions. The Company owns and operates a nitrogen fertilizer plant in East Dubuque, Illinois, that manufactures and sells natural gas-based nitrogen fertilizer products within the corn-belt region in the United States. It is developing energy projects to produce certified synthetic fuels and electric power from carbon-containing materials, such as biomass, waste and fossil resources. Its technologies can produce synthesis gas (syngas) from biomass and waste materials, and convert syngas from its own or other gasification technologies into complex hydrocarbons (the Rentech Process) that are then upgraded into fuels using refining technology that it licenses. In addition to developing projects using these technologies, it is pursuing the licensing of its technologies to developers of projects that are expected to produce fuels and/or power. In May 2011, it acquired majority interest in ClearFuels Technology Inc. In May 2013, Rentech Inc acquired the entire share capital of Fulghum Fibres Inc. In August 2013, Rentech Inc announced that a subsidiary of the Company closed the sale of approximately 450 acres in Natchez, Mississippi to Adams County, Mississippi.
The Rentech Process is a technology based on Fischer-Tropsch (FT) chemistry, which converts syngas that can be produced from a range of biomass, waste and fossil resources into hydrocarbons. These hydrocarbons can be processed and upgraded into synthetic fuels, such as military and commercial jet fuels and low sulfur diesel fuel, as well as waxes and chemicals. Unlike some other alternative transportation fuels, such as ethanol, fuels produced from the Rentech Process can be transported and used in existing infrastructure, including pipelines and engines without blending restrictions. Its technology portfolio also includes the Rentech-SilvaGas biomass gasification technology (the Rentech-SilvaGas Technology), which enables it to offer integrated technologies t! hat can convert biomass and wastes to syngas and into clean fuels and electric power.
The Rentech Process can produce synthetic diesel fuels (RenDiesel1 fuels), which are clean burning having lower emissions of regulated pollutants, such as nitrogen oxides, sulfur oxides and particulate matter, than traditional petroleum-based diesel fuels. The Rentech Process also can produce synthetic jet fuel (RenJet fuel), which when blended with conventional jet fuel meet jet fuel specifications for military jet fuel and commercial Jet A and Jet A-1 fuels. It is developing a proposed project near Natchez, Mississippi (the Natchez Project) designed to produce approximately 30,000 barrels per day of synthetic fuels and chemicals and approximately 120 megawatts of power. It is evaluating alternative configurations for the Natchez site, which would initially be smaller in scale. The alternate configurations may use various feed-stocks alone or in various combinations, and include proportions of waxes and chemicals as products.
The Company owns, through its wholly owned subsidiary, Rentech Energy Midwest Corporation (REMC), a nitrogen fertilizer manufacturing plant that uses natural gas as its feedstock to produce syngas and then nitrogen fertilizer products. The products, the Company can produce include renewable synthetic diesel and jet fuels, naphtha and power from biomass resources; synthetic diesel and jet fuels, naphtha and power from fossil or fossil and biomass resources, and paraffinic waxes, solvents and specialty chemicals.
The Company competes with ExxonMobil, the Royal Dutch/Shell group, Statoil, BP and Sasol.
Advisors' Opinion:- [By Rich Duprey]
Alternative energy specialist�Rentech� (NASDAQ: RTK ) �will be�buying back�up to $25 million worth of company stock through the rest of the year, the board of directors announced Monday.
Top Asian Companies To Watch For 2014: Curtiss-Wright Corporation (CW)
Curtiss-Wright Corporation, together with its subsidiaries, designs, manufactures, and overhauls precision components and systems. It operates in three segments: Flow Control, Motion Control, and Metal Treatment. The Flow Control segment designs, manufactures, and distributes engineered products, including valves, pumps, motors, generators, instrumentation, shipboard systems, and control electronics that manage the flow of liquids and gases, generate power, provide electronic operating systems, and monitor or provide critical functions for naval defense, power generation, oil and gas, and general industrial markets. The Motion Control segment designs, develops, manufactures, and maintains mechanical actuation and drive systems, specialized sensors, motors, electronic controller units, and embedded computing components and control systems for ground defense, aerospace defense, commercial aerospace, and general industrial markets. The Metal Treatment segment provides metallu rgical processing services comprising shot peening, laser peening, specialty coatings and heat treating for commercial and defense aerospace, oil and gas, power generation, automotive, transportation, construction equipment, and miscellaneous metal working industries. The company operates primarily in the United States, the United Kingdom, and Canada. Curtiss-Wright Corporation was founded in 1929 and is headquartered in Parsippany, New Jersey.
Advisors' Opinion:- [By Alex Planes]
In 1917, the two major aircraft manufacturers were forced into a patent pool that would offer modest licensing terms for prospective upstarts. By this point, the Wrights were out of the industry. Wilbur had died years earlier, and Orville had sold his stake to outside investors, leaving Curtiss with an easier path to the dominance previously denied him. The Wrights' reputation was badly damaged, and competition came to the industry despite their efforts. Years later, on the eve of the Great Depression, Curtiss gained a final measure of victory when his company and the Wrights' namesake business merged to become Curtiss-Wright (NYSE: CW ) , which was at the time the largest aviation company in the United States. This company was also briefly a part of the Dow (from 1928 to 1930), making it the first aviation component in the index's history.
No comments:
Post a Comment